Telix Pharmaceuticals Limited

Healthcare · Biotechnology · Australia

Last price 9.51 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 3.22B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney ...